SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid renewed uncertainty surrounding global trade policy, driven by recent tariff decisions that have sparked market volatility. The community is sharply divided, with bears anticipating a major downturn following weekend declines, while bulls expect a typical 'V-shape' recovery, particularly ahead of key tech earnings this week.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly discusses the recent FDA approval of Bysanti for bipolar I disorder and schizophrenia, with many anticipating a significant valuation re-rating and potential for a short squeeze, especially given the drug's patent protection until 2044 and the broader 'mega blockbuster' potential of its pipeline.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community sentiment soars after Hims & Hers pulled its compounded weight-loss pill following regulatory scrutiny and NVO's legal threats, reinforcing the competitive advantage of approved GLP-1 therapies. Many anticipate a significant boost to NVO's market share for its Wegovy pill, with additional buzz surrounding its Super Bowl commercial amplifying discussions on potential sales impact.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending as investors await its earnings report and upcoming presentations of positive Navenibart trial data, a recently acquired long-acting HAE prophylactic. This is fueling community debate between optimism driven by institutional interest and persistent concerns over significant short positions.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending following its corporate update, announcing that its oral obesity drug, VK2735, will advance directly to Phase 3, significantly accelerating its development alongside ongoing late-stage trials for its subcutaneous form. This news has intensified community speculation about a potential major partnership or acquisition, even as some traders express frustration over the stock's immediate price action.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to its succession of record-breaking battery swaps, including hitting 1 million weekly swaps during the Chinese New Year holiday, which bulls highlight as proof of its BaaS ecosystem's strength and a precursor to anticipated profitability. However, the community remains divided, with skeptics dismissing holiday-inflated numbers and alleging continued stock manipulation, while broader discussions also focus on the potential impact of recent tariff rulings.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind (MNKD) is trending with investors focused on its imminent earnings report and CEO presentation, alongside strong anticipation for multiple near-term FDA approvals for pediatric Afrezza and the Furoscix autoinjector, which divide community sentiment between high growth expectations and concerns over past commercialization and executive leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Goldman Sachs BDC, Inc. (NYSE:GSBD) Increases By 25.5%

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 2,633,872 shares, an increase of...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Given Consensus Rating of "Reduce" by Analysts

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) has earned a consensus recommendation of "Reduce" from the five research firms that are covering the company, Marketbeat Ratings reports. Two...

Gladstone Investment (GAIN) Lags Q3 Earnings and Revenue Estimates

Gladstone Investment (GAIN) delivered earnings and revenue surprises of -10.64% and -1.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Goldman Sachs BDC, Inc. Schedules Earnings Release and Conference Call to Announce Fourth Quarter and Fiscal Year Ended 2025 Results

Goldman Sachs BDC, Inc. (GS BDC) (NYSE: GSBD) announced today that it will report its fourth quarter and fiscal year ended December 31, 2025 financial results after the market closes on Thursday...

Goldman Sachs BDC, Inc. Prices Public Offering of $400 Million of 5.100% Unsecured Notes Due 2029 Company Release - January 21, 2026

Goldman Sachs BDC, Inc. (the Company) (NYSE: GSBD) announced today that it has priced an offering of $400 million aggregate principal amount of 5.100% notes due 2029 (the Notes). The Notes will...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Short Interest Up 26.1% in December

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,133,906...

Goldman Sachs BDC, Inc. $GSBD Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. increased its stake in Goldman Sachs BDC, Inc. (NYSE:GSBD - Free Report) by 55.7% in the 3rd quarter, according to the company in its most recent filing with the SEC...

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - Here's Why

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - Here's Why...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Short Interest Update

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 1,692,488 shares, a decline of...

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - What's Next?

Goldman Sachs BDC (NYSE:GSBD) Sets New 12-Month Low - Here's What Happened...

Goldman Sachs BDC, Inc. invests in middle market companies located in the United States. The fund targets companies operating in the fields software, health technology information technology, commercial services and textiles with an investment size of $25 to $75 million and an EBITDA of $5 to $75 million. It provides financing in the form of senior secured debt, unitranche debt, junior secured, mezzanine debt and equity for acquisitions, refinancing, growth, LBOs, dividend recapitalization and restructuring transactions.

GSBD
Goldman Sachs BDC Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GSBD News

GSBDGoldman Sachs BDC Inc